Last reviewed 2026-05-15 · How we verify

[14C]-BI 201335 NA radiolabelled drug

Boehringer Ingelheim · Phase 1 active Small molecule Quality 0/100

[14C]-BI 201335 NA radiolabelled drug is a Small molecule drug developed by Boehringer Ingelheim. It is currently in Phase 1 development.

At a glance

Generic name	[14C]-BI 201335 NA radiolabelled drug
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]-BI 201335 NA radiolabelled drug CI brief — competitive landscape report
[14C]-BI 201335 NA radiolabelled drug updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI

Frequently asked questions about [14C]-BI 201335 NA radiolabelled drug

What is [14C]-BI 201335 NA radiolabelled drug?

[14C]-BI 201335 NA radiolabelled drug is a Small molecule drug developed by Boehringer Ingelheim.

Who makes [14C]-BI 201335 NA radiolabelled drug?

[14C]-BI 201335 NA radiolabelled drug is developed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).

What development phase is [14C]-BI 201335 NA radiolabelled drug in?

[14C]-BI 201335 NA radiolabelled drug is in Phase 1.

Manufacturer: Boehringer Ingelheim — full pipeline
Compare: [14C]-BI 201335 NA radiolabelled drug vs similar drugs
Pricing: [14C]-BI 201335 NA radiolabelled drug cost, discount & access